Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.41 |
| ▸ | YAP1 | P46937 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232944 | 0.95 | CYP8B1 (0.47) | CYP8B1NMT1PRMT5TLR9YAP1 | |
| SCHEMBL1233426 | 0.86 | TLR9 (0.42) | CYP8B1PRMT5TLR9YAP1TLR7 | |
| SCHEMBL1233316 | 0.84 | CKS1B (0.43) | GPR119 | |
| SCHEMBL1233797 | 0.83 | CYP8B1 (0.38) | CYP8B1 | |
| SCHEMBL1231794 | 0.81 | TLR9 (0.44) | CYP8B1PRMT5TLR9YAP1TLR7 | |
| SCHEMBL1233388 | 0.80 | PRMT5 (0.39) | CYP8B1NMT1PRMT5KIT | |
| SCHEMBL1231827 | 0.78 | GBA1 (0.44) | — | |
| SCHEMBL1232966 | 0.75 | MCHR1 (0.49) | NMT1PRMT5KIT | |
| SCHEMBL311936 | 0.73 | PRKDC (0.45) | NMT1PRMT5KIT | |
| SCHEMBL1233343 | 0.72 | GBA1 (0.42) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888349-B2 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | CYP8B1 3218/4885NMT1 4291/4885PRMT5 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.